Status:
TERMINATED
Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)
Lead Sponsor:
Iconic Therapeutics, Inc.
Conditions:
Choroidal Neovascularization
Wet Macular Degeneration
Eligibility:
All Genders
50+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate the safety and effects of repeated intravitreal injections of ICON-1 0.6 mg administered as maintenance therapy or in combination with aflibercept in patients ...
Eligibility Criteria
Inclusion
- Males or females of any race, ≥50 years of age
- Active primary CNV secondary to AMD in the study eye
Exclusion
- Any prior treatment of CNV or advanced AMD in the study eye, except for dietary supplements or vitamins
- Any intraocular or ocular surface surgery (including cataract surgery and laser procedures) in the study eye within 3 months
- Vitrectomy in the study eye
Key Trial Info
Start Date :
March 26 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 25 2019
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT03452527
Start Date
March 26 2018
End Date
April 25 2019
Last Update
April 13 2021
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Site 2
Beverly Hills, California, United States, 90211
2
Site 8
Santa Ana, California, United States, 92705
3
Site 7
Syracuse, New York, United States, 13224
4
Site 3
Ashland, Oregon, United States, 97520